LKB1 signaling and patient survival outcomes in hepatocellular carcinoma.

Pharmacological research 2023 Jun

filter terms:

The liver is a major organ that is involved in essential biological functions such as digestion, nutrient storage, and detoxification. Furthermore, it is one of the most metabolically active organs with active roles in regulating carbohydrate, protein, and lipid metabolism. Hepatocellular carcinoma is a cancer of the liver that is associated in settings of chronic inflammation such as viral hepatitis, repeated toxin exposure, and fatty liver disease. Furthermore, liver cancer is the most common cause of death associated with cirrhosis and is the 3rd leading cause of global cancer deaths. LKB1 signaling has been demonstrated to play a role in regulating cellular metabolism under normal and nutrient deficient conditions. Furthermore, LKB1 signaling has been found to be involved in many cancers with most reports identifying LKB1 to have a tumor suppressive role. In this review, we use the KMPlotter database to correlate RNA levels of LKB1 signaling genes and hepatocellular carcinoma patient survival outcomes with the hopes of identifying potential biomarkers clinical usage. Based on our results STRADß, CAB39L, AMPKα, MARK2, SIK1, SIK2, BRSK1, BRSK2, and SNRK expression has a statistically significant impact on patient survival. Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Citation

Khoa Nguyen, Katherine Hebert, Emily McConnell, Nicole Cullen, Thomas Cheng, Susanna Awoyode, Elizabeth Martin, Weina Chen, Tong Wu, Suresh K Alahari, Reza Izadpanah, Bridgette M Collins-Burow, Sean B Lee, David H Drewry, Matthew E Burow. LKB1 signaling and patient survival outcomes in hepatocellular carcinoma. Pharmacological research. 2023 Jun;192:106757